Meloxicam SBEβCD Composition for Solubility and Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a nonsteroidal anti-inflammatory drug, then anti-inflammatory, analgesic, and antipyretic activities are achieved, but poor aqueous solubility reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent employs a cyclodextrin inclusion complex as an intermediary carrier to solubilize meloxicam. The cyclodextrin molecule has a hydrophobic interior cavity that accommodates the meloxicam molecule, while the exterior remains hydrophilic, enabling aqueous solubility. This mediator resolves the contradiction by allowing meloxicam to be delivered in water-based formulations without compromising its therapeutic activity.
Solution Approach 2:
The patent changes the physical-chemical parameters of meloxicam by forming an inclusion complex with cyclodextrin. This transformation converts the poorly soluble meloxicam into a water-soluble complex, fundamentally altering its solubility parameter while maintaining its pharmacological properties. The complexation reaction changes the molecular environment of meloxicam from hydrophobic to hydrophilic.
2Reliability
If meloxicam is administered to achieve pain relief, then therapeutic effect is obtained, but slow onset of action delays relief
Solution Approach 1:
The cyclodextrin inclusion complex acts as a delivery mediator that facilitates rapid dissolution and absorption of meloxicam. By pre-solubilizing the drug in the cyclodextrin carrier, the formulation eliminates the slow dissolution step that normally delays onset, allowing rapid absorption and faster therapeutic effect.
Solution Approach 2:
The cyclodextrin complexation performs a preliminary solubilization action before administration. The meloxicam is pre-loaded into the cyclodextrin carrier in a soluble form, so that upon administration, no additional dissolution time is required. This preliminary preparation of the drug in a bioavailable state accelerates the onset of action.
3Reliability
If cyclodextrin is used to increase solubility of meloxicam, then bioavailability is enhanced, but formulation complexity increases
Solution Approach 1:
The formulation uses a nested structure where the meloxicam molecule is embedded within the cyclodextrin cavity. This nesting approach consolidates the drug and carrier into a single molecular complex, simplifying the formulation architecture compared to using separate solubilizing agents or complex delivery systems. The nested structure naturally provides both solubility enhancement and stable drug delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.